Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Razak AR, et al. Among authors: walsh w. Br J Cancer. 2011 Mar 1;104(5):756-62. doi: 10.1038/bjc.2011.13. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285985 Free PMC article. Clinical Trial.
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Doyle A, Eisenhauer EA, Oza AM. Kollmannsberger C, et al. Among authors: walsh w. Ann Oncol. 2012 Jan;23(1):238-244. doi: 10.1093/annonc/mdr063. Epub 2011 Mar 29. Ann Oncol. 2012. PMID: 21447615 Free PMC article. Clinical Trial.
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. Goss G, et al. Among authors: walsh w. Invest New Drugs. 2005 Mar;23(2):147-55. doi: 10.1007/s10637-005-5860-y. Invest New Drugs. 2005. PMID: 15744591 Clinical Trial.
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. Among authors: walsh w. Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. doi: 10.1007/s00280-006-0201-1. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528532 Clinical Trial.
848 results